TMTamara Maksimovic

Tamara Maksimovic

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tamara Maksimovic has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Inflammatory Memory of Adipose Tissue Macrophages: From CD68 Footprint to Cardiometabolic and Cancer Risk During Weight Cycling

    by Dragana Tomić Naglić, Mia Manojlović, Slađana Pejaković, Nikolina Vuković, Teodor Grbić, Ognjen Milanović, Milan Mirković, Slobodan Maričić, Tamara Maksimović, Andrijana Milankov

    Obesity is characterized by chronic low-grade inflammation (meta-inflammation) and metabolic dysregulation. Adipose tissue acts as an immunometabolic organ, with macrophages playing a central role. This review examines inflammatory memory in adipose tissue, focusing on CD68+ macrophages and their role in cardiometabolic and cancer risk during weight cycling. (2) Narrative synthesis of evidence from immunology, obesitology, and oncology, with emphasis on macrophage polarization and signaling pathways. (3) Weight cycling induces persistent immune memory in adipose tissue, characterized by exaggerated macrophage responses upon weight regain. CD68+ macrophages contribute to extracellular matrix remodeling, tumor signaling, and metabolic dysfunction. Key mechanisms include PI3K/AKT/mTOR dysregulation, FOXO1/KLF10 axis impairment, and CREB-mediated transcription. This inflammatory memory promotes atherosclerosis progression, insulin resistance, and increased cancer risk, despite prior weight loss. (4) Macrophage-driven inflammatory memory represents a key mechanistic link between obesity, cardiometabolic disease, and cancer. Targeting meta-inflammation independent of body weight should be integral to future therapies.

  • Low-grade serous ovarian cancer: What is new?

    by Tamara Maksimovic, Aljosa Mandic, Dunja Kokanov, Slobodan Maricic, Nemanja Stevanovic, Bojana Gutic-Vukobrat

    Introduction. Low-grade serous ovarian carcinoma is a distinct and relatively uncommon histologic subtype of epithelial ovarian cancer, characterized by unique biological and clinical features that differentiate from high-grade and other epithelial subtypes. Material and Methods. A comprehensive literature search was performed to identify interventional studies, systematic reviews, case reports, and meta-analyses published between 2010 and 2024, focusing on the diagnosis, management, and outcomes of low-grade serous ovarian carcinoma. Diagnosis. Ultrasound is the first-line imaging modality for evaluating ovarian and adnexal lesions. Computed tomography remains the preferred method for staging, treatment planning, and posttherapy monitoring, while magnetic resonance imaging is recommended for characterizing indeterminate adnexal masses or for evaluating extensive disease visualized on ultrasound or computed tomography. Clinical management. For patients with advanced-stage disease (FIGO stages II-IV), maximal cytoreductive surgery followed by six cycles of carboplatin and paclitaxel remains the standard of care. Optimal cytoreduction is associated with significantly improved overall and progressionfree survival compared with suboptimal surgery. Given the intrinsic chemoresistance of low-grade serous ovarian carcinoma, primary cytoreductive surgery is generally favored over neoadjuvant chemotherapy. Emerging targeted therapies focusing on CDK4/6, MAPK, and PI3K/AKT/mTOR pathways, as well as hormonal treatments, are under investigation and have demonstrated encouraging preliminary results. Conclusion. The management of low-grade serous ovarian carcinoma increasingly necessitates an individualized, multidisciplinary approach. Future therapeutic strategies will likely integrate molecularly targeted and endocrine therapies with optimal cytoreductive surgery to improve outcomes for this chemoresistant and biologically distinct ovarian cancer subtype.

  • Neuroendocrine cervical cancer: Have we made any steps forward in its management?

    by Aljosa Mandic, Tamara Maksimovic, Gabrijel-Stefan Nadj, Slobodan Maricic, Aleksander Čelebić


  • Open Access

    Identifying of patients with advanced ovarian cancer experiencing the highest benefit from bevacizumab in the first-line setting on the basis of Kelim score

    by Dunja Kokanov, Tamara Maksimovic, Nemanja Stevanovic, Slobodan Maricic, Sonja Lukac-Paulic, Kristina Savic

    Introduction. Ovarian cancer represents the deadliest gynecological malignancy. The aim of this study is to validate the predictive value of Cancer antigen-125 Elimination rate constant K score regarding progression-free survival among patients with Stage IIIc-IV high-grade serous ovarian cancer according to the International Federation of Gynecology and Obstetrics, treated with bevacizumab. Additionally, the study aims to determine the significance of a score in the assessment of progression-free survival in relation to operation status and disease stage. Material and Methods. The retrospective study was conducted at the Oncology Institute of Vojvodina and included 56 patients treated for high-grade serous ovarian cancer. The treatment protocol consisted of chemotherapy with paclitaxel and carboplatin, followed by bevacizumab maintenance therapy. The Cancer Antigen- 125 Elimination Rate Constant K score was calculated using three Cancer Antigen 125 tumor marker values. Based on this calculation, the score was dichotomized into favorabe (?1) and unfavorable (<1) groups. Results. The analysis of the score?s impact on progression-free survival revealed that patients with a score ?1 had longer mean survival time compared to a score <1 (19.4 vs 17.0 months). This difference was not statistically significant (p=0.549). The operation status in relation to a score was the only statistically significant factor with progression-free survival benefit (p=0.002). Conclusion. In our study, Cancer antigen- 125 Elimination rate constant K score did not emerge as a statistically significant prognostic factor for identifying patients most likely to benefit from bevacizumab. The operative status showed significant predictive value.


  • Open Access

    Comparison of microvascular density in cervical carcinoma in relation to predictive pathohistological parameters

    by Aljosa Mandic, Tatjana Ivkovic-Kapicl, Bojana Gutic, Slobodan Maricic, Nemanja Stevanovic, Nenad Solajic, Zoran Nikin, Tamara Maksimovic, Tijana Stevanovic

    Objective: The occurrence, development, invasion, and metastasis of tumors are closely linked to angiogenesis, which is reflected by tumor microvessel density. The aim is to analyze microvascular density (MVD) in the observed groups of patients with high grade squamos intraepithelial lesions (H-SIL), and cervical carcinoma, and to compare MVD in relation to the degree of tumor differentiation, size, presence of lymphovascular invasion and the presence of lymph node metastases. Materials and methods: The study was retrospective, conducted on histopathological samples of 109 patients who underwent hysterectomy with/without adnexectomy at the Oncology Institute of Vojvodina. Patients were divided into two groups depending on the histopathological results as follows: group A - patients with H-SIL, and group B with cervical cancer. The control group included surgically treated patiens with benign uterine diseases. Based on hematoxylin and eosin staining, representative sample was chosen for immunohistochemistry, and the analysis of CD34 antigen expression and measurement of MVD were done. Results: In order to subdivide groups according to the low (L) and high (H) MVD, in control group, group A, and B, with mean MVDs 2.2; 9.85 and 17.19, respectively, a cut-off values were determined. In the control group, LMVD 100% was measured in the all examined samples. There were 7 (21.21%) in group A and 29 patients (63.04%) in group B with HMVD. A statistically significant difference was confirmed by comparing HMVD and LMVD in cervical cancer patients with lymph nodes metastasis (p<0.029). In the subgroup of patients with other worse pathohistological prognostic factors, a tumor size greater than 2 cm, depth of stromal invasion ?10 mm, infiltration of ?isthmus? of the uterus, a difference with no statistical significance was confirmed. Conclusion: Invasive cervical cancers are characterised by a significantly higher mean values of microvascular density compared to H-SIL. Significantly more often, HMVD is associated with the presence of lymph node metastases and with histopathological parameters of poor prognosis in patients with cervical cancer.

  • Open Access

    Survival analysis of patients with rare tumors of the uterine corpus – carcinosarcoma

    by Nemanja Stevanovic, Aljosa Mandic, Slobodan Maricic, Gabriel Stefan Nadj, Tamara Maksimovic, Nevena Stanulovic, Vladimir Cancar, Milan Rodic

    Background/Aim. Uterine carcinosarcoma (UCS), formerly known as malignant mixed M?llerian tumor, is a rare, aggressive malignancy of the female genital tract. The aim of this study was to analyze the most important clinical and pathohistological characteristics of UCSs on operated patients, as well as to determine which of those factors are affecting progression-free survival (PFS) and overall survival (OS) of patients. Methods. The study was conducted as a retrospective analysis of medical data documentation of patients with a diagnosis of UCS who were surgically treated at the Department of Gynecology, Clinic for Operative Oncology, Oncology Institute of Vojvodina, Sremska Kamenica, Serbia, in 10 years? period (from the beginning of 2009 to the end of 2018). The analysis included data for a total of 31 patients. Results. Of all the examined parameters (age of the patient, clinical stage of the disease, histological grade, depth of myometrial invasion, and lymphovascular invasion ? LVI), the greatest influence on the choice of therapeutic procedure had a histological tumor grade. Conclusion. Our research showed the joint influence of the examined clinical and pathohistological factors on PFS and OS of patients with UCS. The only independent parameter that showed a statistically significant impact on survival is LVI.

  • Malignant pleural effusion in patients with ovarian cancer

    by Tamara Maksimovic, Aljosa Mandic, Sinisa Maksimovic, Ivan Kuhajda, Milorad Bijelovic, Nemanja Stevanovic

    Introduction. Ovarian cancer is the most lethal gynecological cancer. The most common manifestation of thoracic metastasis is pleural effusion. Pleural effusion with positive cytology is regarded as stage IVa of the International Federation of Gynecology and Obstetrics classification, and the overall five-year survival in these patients is less than 20%. We analyzed the data of patients with ovarian cancer who were treated at the Oncology Institue of Vojvodina, in order to establish the incidence of malignant pleural effusions, laterality of pleural effusions, and clinical manifestations. Material and Methods. The study included 731 patients with ovarian cancer who were treated at the Oncology Institue of Vojvodina from January 2012 to May 2020. The obtained data were compared with data found in the literature in the same period. Results. The incidence of malignant pleural effusion in our study was 5.75%; right-sided pleural effusion was found in 57.15% of patients, 33.33% of patients had effusion on the left side, and 9.52% had bilateral effusions. Thus, unilateral effusion was found in 90.48% of cases, and bilateral in only 9.52%. The most common symptom was dyspnea, reported in 33 patients (78.6%). Conclusion. The incidence of malignant pleural effusion in our study was most similar to data found by Zamboni et al. published in 2015; the right side was the dominant side of pleural effusions. The most common symptoms were dyspnea, shortnes of breath and chest pain.